Cases & Deals

Viveris Management and Amundi Private Equity Funds grant exclusive acquisition option to Actelion for Trophos acquisition

Clients Viveris Management and Amundi Private Equity Funds

Jones Day advised Viveris Management and Amundi Private Equity Funds, shareholders of Trophos SA, a clinical stage pharmaceutical company, in connection with the €10 million (US$12.9 million) exclusive acquisition option granted to Actelion Ltd. for a final acquisition price between €125 million (US$162 million) and €195 million (US$253 million) in cash, contingent upon various regulatory approvals and other clinical progress.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.